Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. was originally incorporated in Delaware in 2001, emerging from a reverse merger with a shell company. The firm is led by CEO James Parslow, who also serves as a director, and has historically focused on its poly- and monoclonal antibody pipeline. Wealth origin is not publicly attributed to a single family; the company's capital has been raised through public equity offerings. The firm's strategy centers on its proprietary glycan engineering platform, which modifies therapeutic proteins to improve half-life and efficacy. Xenetic's lead candidate, XB-301, is an anti-PSMA antibody for prostate cancer, developed in partnership with a undisclosed collaborator. The company also holds rights to a COVID-19 vaccine candidate. Geographically, operations have been primarily in the United States, with some research ties to Russia and Europe. Xenetic is a publicly traded entity (NASDAQ: XBIO) with a small market capitalization, typically below $50 million. The firm employs fewer than 10 professionals, based on public filings. It maintains no disclosed additional offices beyond its stated headquarters in Oxford, Massachusetts. The company has not announced any recent operational events in the last 24 months. A structural differentiator is Xenetic's status as a publicly traded biotech C-corporation, not a family office or private investment vehicle. It does not manage external capital for allocators, and its governance follows SEC regulations rather than family office structures. This public-company architecture limits its ability to pursue long-term, illiquid bets typical of family offices.